Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CSK Monoclonal Antibody (C.678.4)
Rabbit Monoclonal Antibody
Supplier: Invitrogen™ MA514915
Description
It is not recommended to aliquot this antibody. This antibody is not cross-reactive with other proteins.
CSK is a tyrosine kinase that has been shown to downregulate the activity of SRC oncoprotein through phosphorylation of its carboxy terminus. Since cell transformation by SRC is caused by various mechanisms that interfere with this phosphorylation, the CSK gene might function as an antioncogene. CSK plays an important role in the regulation of cell growth, differentiation, migration, and immune responses. CSK phosphorylates tyrosine residues located in the C-terminal tails of Src-family kinases including LCK, SRC, HCK, FYN, LYN, CSK, and YES1. CSK is expressed ubiquitously as a protein of approximately 50 KDa in cytosol, but a fraction distributes to lipid rafts due to interaction with the lipid raft-associated protein PAG (Csk-binding protein).
Specifications
CSK | |
Monoclonal | |
Unconjugated | |
CSK | |
AW212630; CSK; CSK, non-receptor tyrosine kinase; C-SRC kinase; c-src tyrosine kinase; C-terminal Src kinase; MGC117393; p50CSK; protein-tyrosine kinase (CSK); protein-tyrosine kinase CYL; Protein-tyrosine kinase MPK-2; Tyrosine-protein kinase CSK | |
Rabbit | |
Affinity chromatography | |
RUO | |
100154110, 12988, 1445, 315707 | |
-20°C | |
Liquid |
Western Blot | |
C.678.4 | |
0.01M HEPES with 100μg/mL BSA, 50% glycerol, 0.15M NaCl and <0.02% sodium azide; pH 7.5 | |
P32577, P41240, P41241 | |
CSK | |
Synthetic peptide corresponding to residues surrounding amino acid residue Val399 of human Csk. | |
100 μL | |
Primary | |
Human, Mouse, Rat, Monkey, Pig | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction